Quotient Therapeutics

🎂🧬 Today we celebrate the birthday of Rosalind Franklin, whose groundbreaking X-ray diffraction work was key to discovering #DNA's structure. Her legacy has paved the way for our work in #SomaticGenomics and inspires our innovations every day.

Companies pioneering original science are key to discovering new medicines. As we explore our #SomaticGenomics platform, we’re proud to be part of the #FlagshipFounded ecosystem of companies, and the many more to come, taking bold scientific leaps for a better future for all.

Our academic co-founders contributed to this 2023 study published in Cell Press, highlighting how somatic mutations in liver cells can help to identify adaptive pathways in metabolic liver disease. The research is encouraging as we explore the possibilities of our #SomaticGenomics Platform and human target selection. Read the study here: https://bit.ly/4eCnQfT

Did you know that natural selection conducts a process akin to a clinical trial at the cellular level to test somatic mutations, allowing Quotient to identify which ones are beneficial vs. neutral vs. disease-causing? Learn how we're leveraging these insights to develop novel medicines that imitate or inhibit a variant's impact: https://bit.ly/3z6OQDW

This week, we hosted Flagship Pioneering CEO Noubar Afeyan at our UK lab! We're proud to be a part of Flagship's strategic commitment to the UK and look forward to growing Quotient as a vital piece of this biotech community with our #SomaticGenomics platform.

With every decade since the #HumanGenomeProject, we are learning more about genetics and using those insights to create potential new ways to cure, prevent or reverse disease. Read more about our work at Quotient and insights from our CEO, Geoffrey von Maltzahn, in this article from the Toronto Star: https://bit.ly/3XtCa4f

Our work at Quotient is guided by our core values: 🧪 Divergent, convergent, selective and adaptive 🎯 Driven to act and impact 🤝 Grounded in community Learn how our curious and data-driven pioneers drive the exploration of a new field of #genetics: https://bit.ly/4aPdAxD

Want to learn more about our #SomaticGenomics platform? Our head of platform, Simon Brunner, discusses how our technology allows us to identify the most promising targets for #DrugDevelopment in this SEQanswers article. Check it out here: https://bit.ly/4bShGGK

🎙️ In the latest episode of the Drug Target Review podcast, our co-founder and president Jacob Rubens discusses the potential of #SomaticGenomics to improve #DrugDeveloment, as well as innovations shaping the future of molecular biology. Listen now: https://bit.ly/3Ra7QYl

At Quotient, we look to our own biology to inform our path. We align #DrugDevelopment with the optimal therapeutic approach. Our platform's flexibility allows us to view any modality, from small molecules to antibodies, antisense oligonucleotides, and beyond, as a tool to build real-world medicines using #SomaticGenomics. Learn more here: https://lnkd.in/g2VM5qJ6